Pay in 4 interest-free payments of $6.80 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Pertenece a una clase de frmacos conocidos como agonistas de los receptores GLP-1 y GIP, que imitan a las hormonas naturales que regulan el apetito, el azcar en sangre y el metabolismo
Key Industry Highlights: Dominant Segment : Ozempic leads the GLP-1 receptor agonist market in 2025 , with a 32.1% share , driven by its strong clinical efficacy in HbA1c reduction, proven cardiovascular benefits, and superior weight-loss outcomes
Predominantly located in the ganglion cell layer of the retina with additional sparse expression detected in the inner nuclear layer and outer nuclear layer, GLP-1R was found to be expressed at high levels in the retina, even surpassing in tissues like the liver and bowel
Data from clinical trials on FDA-approved semaglutide products (such as Ozempic or Wegovy) do not necessarily apply to compounded semaglutide, and individual results may vary
US$ 27.66
US$ 28.92
US$ 21.29
US$ 27.52
US$ 23.99
US$ 19.99
